IRTC

SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the third quarter 2026 after the close of trading on Thursday, November 5, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at iRhythm Holdings, Inc.

SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.

Following completion of the forensic investigation, company begins notifying impacted individuals Following completion of the forensic investigation, company begins notifying impacted individuals

iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.

iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.

iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.